Symptom Evaluation After Cessation of a Proton Pump Inhibitor in Healthy Volunteers
NCT ID: NCT00915239
Last Updated: 2009-06-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2006-01-31
2006-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Clinical Significance of Acid Rebound in Functional Dyspepsia
NCT01373970
PPI-Rebound-Trial. A Study of the Clinical Relevance of the Acid Rebound Phenomena
NCT00526006
A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants
NCT07329972
On-Demand Use of Pantoprazole: Determinants for Chronic Use of Acid Suppressive Medication
NCT00161096
PPI and Microbiome in Healthy Volunteers and Functional Dyspepsia
NCT03545243
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pantoprazole
Pantoprazole
40 mg pantoprazole once daily for 28 days
Placebo
Placebo
identical placebo once daily for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Pantoprazole
40 mg pantoprazole once daily for 28 days
Placebo
identical placebo once daily for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-70 years of age
* Informed consent
* No prior history of any GI disorder
Exclusion Criteria
* H. pylori infection
* Ongoing treatment with pain-relieving medications (i.e., NSAID)
* Pregnancy or breast feeding
18 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sahlgrenska University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sahlgrenska University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sahlgrenska Univeristy Hospital
Gothenburg, Gothenburg, Sweden
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SUS/KUS2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.